Compare Prospect Capital Corporation (PSEC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs GeneDx Holdings Corp — how do they compare? Prospect Capital Corporation trades at $1.8 (market cap $974.22M), while GeneDx Holdings Corp trades at $69.42 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.1× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and GeneDx Holdings Corp for 19 Days on average.
| PSEC | WGS | |
|---|---|---|
Market Cap | $974.22M | $2.02B |
Volume | 5,779,996 | 734,640 |
Sector | Financials | Health |
52-Week High | $3.05 | $167.51 |
52-Week Low | $1.82 | $34.51 |
Typical Hold Time | 78 Days | 19 Days |
Enterprise Value | $2.73B | $2.05B |
Dividend Yield | 23.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.84, up 0.55% on the day, with a bearish technical signal from moving averages despite bullish RSI readings. The company reported negative revenue and net income for 2025, though recent quarterly EPS have beaten expectations. Dividend distributions continue, but analyst consensus is mixed with a majority hold rating. Recent news highlights distribution announcements and management commentary on lower middle-market opportunities.
The outlook is cautious; PSEC's high yield and low P/B ratio present value, but persistent negative cash flow, volatile profitability, and a bearish technical trend pose significant risks. Investor sentiment is divided, with concerns over NAV erosion and portfolio contraction offset by income-focused appeal.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
